Literature DB >> 23928114

Fetuin-A is linked to improved glucose tolerance after short-term exercise training in nonalcoholic fatty liver disease.

Steven K Malin1, Anny Mulya, Ciaran E Fealy, Jacob M Haus, Mangesh R Pagadala, Amanda R Scelsi, Hazel Huang, Chris A Flask, Arthur J McCullough, John P Kirwan.   

Abstract

Fetuin-A is synthesized in the liver and may be associated with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Lifestyle-induced weight loss reduces fetuin-A, but the effect of exercise alone is unknown. We determined the effect of short-term exercise training on plasma fetuin-A in 13 (50.5 ± 3.4 yr) obese adults (body mass index, 33.3 ± 0.9 kg/m(2)) with clinically diagnosed NAFLD. Subjects participated in 7 days of supervised exercise training (60 min/day at ∼85% maximum heart rate) and were instructed to maintain their normal caloric and macronutrient intake. Insulin resistance was assessed by an oral glucose tolerance test. Hepatic triglyceride content (HTGC) was determined by proton MRI. We used C2C12 skeletal muscle cells to examine the direct effect of fetuin-A on 2-deoxyglucose uptake, insulin signaling [phosphorylation of Akt and AS160 (pAkt and pAS160, respectively)], and glucose transporter-4 (GLUT-4) translocation. Insulin resistance was reduced by 29% (P < 0.05), and glucose area under the curve (AUC) was decreased by 13% (P < 0.01) after the 7 days of exercise. Furthermore, circulating fetuin-A was decreased by 11% (4.2 ± 03 vs. 3.6 ± 0.2 nM; P < 0.02), and this change correlated with reduced insulin resistance (r = 0.62; P < 0.04) and glucose AUC (r = 0.58; P < 0.04). Importantly, the exercise program did not change body weight (P = 0.12), HTGC (P = 0.73), or aerobic capacity (P = 0.14). In vitro experiments revealed that fetuin-A decreased skeletal muscle glucose uptake by downregulating pAkt and pAS160 and subsequent GLUT-4 translocation to the plasma membrane. Together, our findings highlight a role for fetuin-A in skeletal muscle insulin resistance and suggest that part of the exercise-induced improvement in glucose tolerance in patients with NAFLD may be due to lowering fetuin-A.

Entities:  

Keywords:  hyperglycemia; inflammation; insulin sensitivity; obesity

Mesh:

Substances:

Year:  2013        PMID: 23928114      PMCID: PMC3798818          DOI: 10.1152/japplphysiol.00237.2013

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  44 in total

1.  Effects of HRT and exercise training on insulin action, glucose tolerance, and body composition in older women.

Authors:  E M Evans; R E Van Pelt; E F Binder; D B Williams; A A Ehsani; W M Kohrt
Journal:  J Appl Physiol (1985)       Date:  2001-06

2.  Regular exercise enhances insulin activation of IRS-1-associated PI3-kinase in human skeletal muscle.

Authors:  J P Kirwan; L F del Aguila; J M Hernandez; D L Williamson; D J O'Gorman; R Lewis; R K Krishnan
Journal:  J Appl Physiol (1985)       Date:  2000-02

Review 3.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

4.  Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans.

Authors:  Norbert Stefan; Anita M Hennige; Harald Staiger; Jürgen Machann; Fritz Schick; Stefan M Kröber; Fausto Machicao; Andreas Fritsche; Hans-Ulrich Häring
Journal:  Diabetes Care       Date:  2006-04       Impact factor: 19.112

5.  Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women.

Authors:  Sae Jeong Yang; Ho Cheol Hong; Hae Yoon Choi; Hye Jin Yoo; Geum Ju Cho; Teak Geun Hwang; Sei Hyun Baik; Dong Seop Choi; Seon Mi Kim; Kyung Mook Choi
Journal:  Clin Endocrinol (Oxf)       Date:  2011-10       Impact factor: 3.478

6.  Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss.

Authors:  Johanna Maria Brix; Harald Stingl; Florian Höllerl; Gerit Holger Schernthaner; Hans-Peter Kopp; Guntram Schernthaner
Journal:  J Clin Endocrinol Metab       Date:  2010-07-21       Impact factor: 5.958

Review 7.  Exercise and insulin: Convergence or divergence at AS160 and TBC1D1?

Authors:  Gregory D Cartee; Katsuhiko Funai
Journal:  Exerc Sport Sci Rev       Date:  2009-10       Impact factor: 6.230

8.  Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes.

Authors:  Anke Tönjes; Mathias Fasshauer; Jürgen Kratzsch; Michael Stumvoll; Matthias Blüher
Journal:  PLoS One       Date:  2010-11-09       Impact factor: 3.240

9.  Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults.

Authors:  Krupa Shah; Abby Stufflebam; Tiffany N Hilton; David R Sinacore; Samuel Klein; Dennis T Villareal
Journal:  Obesity (Silver Spring)       Date:  2009-04-23       Impact factor: 5.002

10.  Development regulation of the subcellular distribution and glycosylation of GLUT1 and GLUT4 glucose transporters during myogenesis of L6 muscle cells.

Authors:  Y Mitsumoto; A Klip
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

View more
  21 in total

1.  Visceral and subcutaneous adipose tissue express and secrete functional alpha2hsglycoprotein (fetuin a) especially in obesity.

Authors:  Diego Pérez-Sotelo; Arturo Roca-Rivada; María Larrosa-García; Cecilia Castelao; Iván Baamonde; Javier Baltar; Ana Belen Crujeiras; Luisa María Seoane; Felipe F Casanueva; María Pardo
Journal:  Endocrine       Date:  2016-10-14       Impact factor: 3.633

2.  Exercise-induced lowering of fetuin-A may increase hepatic insulin sensitivity.

Authors:  Steven K Malin; Juan Pablo del Rincon; Hazel Huang; John P Kirwan
Journal:  Med Sci Sports Exerc       Date:  2014-11       Impact factor: 5.411

Review 3.  Nonmedicinal interventions in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Radu M Nanau; Lawrence B Cohen
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jun-Jul

4.  Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.

Authors:  Konstantinos Kargiotis; Vasilios G Athyros; Olga Giouleme; Niki Katsiki; Evangelia Katsiki; Panagiotis Anagnostis; Chrysoula Boutari; Michael Doumas; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

Review 5.  Fetuin-A: a novel link between obesity and related complications.

Authors:  J F Trepanowski; J Mey; K A Varady
Journal:  Int J Obes (Lond)       Date:  2014-12-03       Impact factor: 5.095

Review 6.  The association between circulating fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies.

Authors:  F Roshanzamir; M Miraghajani; M H Rouhani; M Mansourian; R Ghiasvand; S M Safavi
Journal:  J Endocrinol Invest       Date:  2017-06-22       Impact factor: 4.256

7.  AMP-activated Protein Kinase (AMPK): Does This Master Regulator of Cellular Energy State Distinguish Insulin Sensitive from Insulin Resistant Obesity?

Authors:  X Julia Xu; Rudy J Valentine; Neil B Ruderman
Journal:  Curr Obes Rep       Date:  2014-06-01

8.  AMP activated kinase negatively regulates hepatic Fetuin-A via p38 MAPK-C/EBPβ/E3 Ubiquitin Ligase Signaling pathway.

Authors:  Vishal Kothari; Jeganathan Ramesh Babu; Suresh T Mathews
Journal:  PLoS One       Date:  2022-05-06       Impact factor: 3.240

9.  Relation of Serum and Vitreous Concentrations of Fetuin-A with Diabetic Retinopathy.

Authors:  Chunming Zhao; Jiangping Hou; Shengxi Wang; Rui Jiang
Journal:  Med Sci Monit       Date:  2015-06-25

Review 10.  Pathophysiology of Non Alcoholic Fatty Liver Disease.

Authors:  Salvatore Petta; Amalia Gastaldelli; Eleni Rebelos; Elisabetta Bugianesi; Piergiorgio Messa; Luca Miele; Gianluca Svegliati-Baroni; Luca Valenti; Ferruccio Bonino
Journal:  Int J Mol Sci       Date:  2016-12-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.